α cells use both PC1/3 and PC2 to process proglucagon peptides and control insulin secretion
Science Advances · 2025
DOI: 10.1126/sciadv.ady8048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Canqi Cui und 13 weiteren Autor:innen. Beteiligte Einrichtung: Duke Molecular Physiology Institute, Durham, NC, USA. Hauptthemen laut MEDLINE: Proglucagon, Glucagon-Secreting Cells, Insulin Secretion, Proprotein Convertase 1. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
α cells secrete proglucagon peptides to regulate nutrient metabolism. Recent findings support an α cell–to–β cell axis that is mediated by paracrine signaling through the glucagon receptor and glucagon-like peptide 1 (GLP-1) receptor in β cells. To address which proglucagon peptides stimulate insulin secretion, we developed an assay to quantify levels of GLP-1(7–36)NH 2 . We also generated three transgenic mouse lines that allow α cell-specific, inducible deletion of the genes for the two prohormone convertase enzymes that process proglucagon . Our studies reveal that both mouse and human islets contain GLP-1(7–36)NH2, but glucagon mediates α cell–to–β cell communication in mice. However, in the absence of normal production of glucagon, α cells up-regulate prohormone convertase 1 (PC1/3) to generate GLP-1 and enhance glucose tolerance. Human islets have substantially higher levels of GLP-1 than mice, which positively correlate with rates of insulin secretion. These studies show plasticity in proglucagon processing to support α cell–to–β cell communication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Duke Molecular Physiology Institute, Durham, NC, USA.
- Division of Endocrinology, Department of Medicine, Duke University, Durham, NC, USA.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
- Departments of Surgery and Pathology and Laboratory Medicine, Faculty of Medicine, BC Children's Hospital Research Institute and Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver,…
- Diabetes, Obesity and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
- Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
ORCID-Profile: Canqi Cui, Sarah M Gray, Kimberley El, Alex Chen, Paul A Grimsrud, Jessica O Becker, Austin Taylor, Guo-Fang Zhang, Kyle W Sloop, Andrew N Hoofnagle, David A D'Alessio, Jonathan E Campbell
Förderung
- NIDDK NIH HHS
Zitieren
APA
Cui, C., Leander, D. C., Gray, S. M., El, K., Chen, A., Grimsrud, P. A., Becker, J. O., Taylor, A., Zhang, G. F., Sloop, K. W., Verchere, C. B., Hoofnagle, A. N., D'Alessio, D. A., & Campbell, J. E. (2025). α cells use both PC1/3 and PC2 to process proglucagon peptides and control insulin secretion. Science Advances. https://doi.org/10.1126/sciadv.ady8048
Vancouver
Cui C, Leander DC, Gray SM, El K, Chen A, Grimsrud PA, et al. α cells use both PC1/3 and PC2 to process proglucagon peptides and control insulin secretion. Science Advances. 2025. doi:10.1126/sciadv.ady8048
BibTeX
@article{Cui2025,
author = {Cui, Canqi and Leander, Danielle C and Gray, Sarah M and El, Kimberley and Chen, Alex and Grimsrud, Paul A and Becker, Jessica O and Taylor, Austin and Zhang, Guo-Fang and Sloop, Kyle W and Verchere, C Bruce and Hoofnagle, Andrew N and D'Alessio, David A and Campbell, Jonathan E},
title = {α cells use both PC1/3 and PC2 to process proglucagon peptides and control insulin secretion},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.ady8048}
}
EUVIMED